No Data
No Data
格隆汇公告精选(港股)︱北海康成-B(01228.HK): CAN103, used to treat Gaucher's disease (GD), obtains priority review qualification.
【Today's Focus】Beihai Kangcheng-B (01228.HK): CAN103 for the treatment of Gaucher's Disease (GD) granted priority review qualification Beihai Kangcheng-B (01228.HK) announcement, CAN103 (Velaglucerase Beta) for the treatment of Gaucher's Disease (GD) has been granted priority review qualification by the National Medical Products Administration Drug Approval Center. The granting of priority review qualification to CAN103 (Velaglucerase Beta) recognizes the urgent medical needs of GD patients in china and the advantages of the company's clinical trial results. The company is making every effort to accelerate the approval process of CAN103 (Velaglucerase Beta) to make it the first one.
ZX Inc. Unveils New Game Beta Test Launch
zx inc (09890.HK) is planning to officially start the public beta of its first open-world game "Douro Mainland: Legend of the Evil" on October 10.
Grinding Media reported on September 30th that zx inc (09890.HK) announced that the group's first open-world game, "Douro Mainland: The Legend of Extermination," will officially start public testing on October 10, 2024. At that time, the first test will be conducted for 7 days on the Android platform in mainland China. "Douro Mainland: The Legend of Extermination" is an open-world adventure game launched by the group in 2024, authorized by the official version of "Douro Mainland," and successfully obtained dual IP authorization from china lit (stock code: 0772) and Tencent Video. The game is developed by kingnet network co., ltd. (stock code: SZ.002517.
ZX INC: INTERIM REPORT 2024
ZX Inc. Enhances Presence With Strategic Relocation
A quick look at the mid-term performance of Zhongxu Future (9890.HK) in 2024.
Recently, Zhongxu Future (9890.HK) released the financial report for the first half of 2024, a picture to help you understand.
No Data
No Data